• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Raised Guidance May Change The Case For iRhythm Stock

    Simply Wall St·11/08/2026 10:31:03
    Listen to the news
    • iRhythm Holdings reported third quarter 2026 sales of US$221.59 million and a net loss of US$29.85 million, raised full year revenue guidance to a range of US$890 million to US$895 million, and incorporated initial VitalConnect contributions.
    • Management is relying on the Zio Monitor engine while delaying the next generation Zio MCT FDA submission and focusing on VitalConnect integration, which shifts the near term balance between product refresh, regulatory risk, and platform build out.
    • The focus now turns to how iRhythm Holdings' investment narrative incorporates the raised guidance alongside the delayed next generation Zio MCT filing.
    Spot 35 healthcare AI stocks that, like iRhythm Holdings, are trying to balance growth ambitions, regulatory timelines and profitability in data driven cardiac and broader digital health markets.

    iRhythm Holdings Investment Narrative Recap

    To own iRhythm Holdings, you need to believe its Zio platform and broader cardiac monitoring services keep winning more volume and better economics over time, despite current losses. In the near term, the story leans on execution in Zio Monitor and disciplined expense control. The widened third quarter loss keeps the profitability path in focus but does not appear to change that core thesis.

    The key short term catalyst is whether raised 2026 revenue and margin guidance can still be met while VitalConnect is integrated and the next generation Zio MCT filing waits until 2027. The biggest operational risk sits with regulatory timelines and compliance costs, which could weigh further on losses if delays persist.

    The raised 2026 outlook looks most relevant here. Management now guides to US$890 million to US$895 million in full year sales, including around US$16 million from VitalConnect, and a higher adjusted EBITDA margin range of 15.5% to 16%. That targets more efficient operations on a larger base, even as GAAP net loss widened in the third quarter.

    For you as a shareholder, the question is how that guidance interacts with the delayed Zio MCT submission and softer Zio AT demand. Execution on integrating VitalConnect, keeping Zio Monitor growth healthy, and managing regulatory workstreams will likely set the tone for the next phase of the iRhythm Holdings story, rather than short term share price volatility.

    iRhythm Holdings' current analyst narrative points to revenues of US$1.3b and earnings of US$86.1 million by 2029, based on an assumed yearly top line growth rate of 15.5%. That path implies an earnings swing of about US$100 million from the reported loss of US$13.9 million today to the forecast profit, with 2029 framed as the key reference year for those consensus figures.

    Uncover why iRhythm Holdings' fair value indicates a 90% potential upside to its current price that may not last much longer.

    NasdaqGS:IRTC 1-Year Stock Price Chart
    NasdaqGS:IRTC 1-Year Stock Price Chart

    Exploring Other Perspectives

    One alternate view focuses on the risk that iRhythm Holdings leans too hard on primary care and hospital workflow adoption. The most cautious analysts worried that slower EHR integration and stickier legacy Holter use could cap progress, even while still penciling in roughly US$1.3b of revenue and about US$87.7 million of earnings by 2029. Those projections, set before this latest guidance raise, show how far opinions can spread. Consider using them as a prompt to explore several different scenarios before deciding how this new earnings update might reshape your own narrative.

    Explore another iRhythm Holdings fair value estimate, including one that suggests it could be worth just $171.33!

    Decide For Yourself

    Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so consider relying on your own analysis.

    Looking for more investment ideas beyond iRhythm Holdings?

    If the iRhythm Holdings story has sharpened your thinking, it can help to compare it with other companies that line up with your own risk, income, and quality preferences. The Simply Wall St Screener lets you filter the market down to a focused shortlist so you can pressure test your thesis across different business models and balance sheet profiles.